YD Bio Ltd key statistics and ratios

In fiscal 2025, YD Bio Ltd had an operating margin of -883.3% and a current ratio of 5.88. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

YD Bio Ltd: financial ratios, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Gross margin	43.8%	30.4%	28.1%
Operating margin	−2.8%	−286.5%	−883.3%
Net margin	3.9%	−276.6%	<−999%
Free-cash-flow margin	−16.0%	−254.3%	<−999%
Return on equity	59.0%	−42.7%	—
Return on assets	—	−20.6%	−80.5%
Asset turnover	—	0.07	0.06
Current ratio	—	13.18	5.88
Debt to equity	0.0%	0.0%	—
Interest cover (operating income ÷ interest)	n/m	n/m	—
Effective tax rate	23.2%	—	—
R&D as % of revenue	—	96.3%	268.4%
Capital spending as % of revenue	0.1%	14.7%	241.3%
Free cash flow ÷ net income	−412.6%	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 5 checks passed · December 31, 2025

What it owns · $14m

Short-term assets $10mLonger-term assets $4m

What it owes, and who funded it · $17m

Short-term liabilities $2mLonger-term liabilities $15mShareholders' equity $-3m

Short-term assets cover short-term liabilities $10m of assets due within a year against $2m of liabilities due within a year.
Short-term assets cover long-term liabilities $10m short-term assets against $15m of longer-dated liabilities.
More cash than debt $6m of cash against $6,764 of debt.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt −$7m of operating cash flow against $6,764 of debt.
Operating profit covers interest at least five times over No material interest expense reported.

From YD Bio Ltd's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ISPC vs YDES QSI vs YDES BGLC vs YDES ACON vs YDES

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from YD Bio Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to YD Bio Ltd.